Insider Selling: Amphastar Pharmaceuticals (NASDAQ:AMPH) CFO Sells 8,180 Shares

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) CFO William Peters sold 8,180 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $22.48, for a total value of $183,886.40. Following the completion of the sale, the chief financial officer owned 172,846 shares in the company, valued at $3,885,578.08. This represents a 4.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Amphastar Pharmaceuticals Price Performance

Amphastar Pharmaceuticals stock traded up $0.11 during midday trading on Tuesday, reaching $20.42. 363,292 shares of the stock traded hands, compared to its average volume of 532,151. The stock has a market cap of $868.63 million, a P/E ratio of 12.08, a PEG ratio of 4.39 and a beta of 0.89. The stock’s fifty day moving average is $19.70 and its 200-day moving average is $21.32. The company has a quick ratio of 1.71, a current ratio of 2.40 and a debt-to-equity ratio of 0.79. Amphastar Pharmaceuticals, Inc. has a 12 month low of $16.65 and a 12 month high of $31.26.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.29. The business had revenue of $183.90 million for the quarter, compared to analysts’ expectations of $179.92 million. Amphastar Pharmaceuticals had a return on equity of 14.98% and a net margin of 10.76%. As a group, equities research analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 2.25 EPS for the current year.

Institutional Trading of Amphastar Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Quarry LP bought a new stake in shares of Amphastar Pharmaceuticals during the third quarter worth $32,000. Farther Finance Advisors LLC grew its holdings in shares of Amphastar Pharmaceuticals by 46.3% in the fourth quarter. Farther Finance Advisors LLC now owns 1,381 shares of the company’s stock worth $37,000 after purchasing an additional 437 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Amphastar Pharmaceuticals by 24.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,233 shares of the company’s stock worth $60,000 after purchasing an additional 435 shares during the last quarter. TD Private Client Wealth LLC increased its stake in Amphastar Pharmaceuticals by 410.1% in the 4th quarter. TD Private Client Wealth LLC now owns 2,418 shares of the company’s stock worth $65,000 after buying an additional 1,944 shares during the period. Finally, Tower Research Capital LLC TRC lifted its holdings in Amphastar Pharmaceuticals by 263.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,583 shares of the company’s stock valued at $82,000 after buying an additional 2,596 shares in the last quarter. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Wall Street Analysts Forecast Growth

AMPH has been the subject of a number of recent research reports. Wall Street Zen raised shares of Amphastar Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday. Wells Fargo & Company lifted their price target on Amphastar Pharmaceuticals from $19.00 to $20.00 and gave the stock an “equal weight” rating in a research report on Friday. Zacks Research raised Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 21st. Bank of America restated an “underperform” rating and set a $20.00 price objective (down from $25.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, June 29th. Finally, Barclays decreased their price target on Amphastar Pharmaceuticals from $23.00 to $20.00 and set an “equal weight” rating on the stock in a report on Wednesday, June 3rd. Six analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus price target of $22.00.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.